학술논문
Management of Antineutrophil Cytoplasmic Antibody--Associated Vasculitis with COVID-19: A Single Center Experience.
Document Type
Article
Author
Source
Subject
*VASCULITIS treatment
*AUTOIMMUNE disease treatment
*CHRONIC kidney failure
*COVID-19
*AUTOIMMUNE diseases
*ANTINEUTROPHIL cytoplasmic antibodies
*TREATMENT effectiveness
*RISK assessment
*CYCLOPHOSPHAMIDE
*CASE studies
*GLOMERULONEPHRITIS
*VASCULITIS
*DISEASE risk factors
*DISEASE complications
*
*
*
*
*
*
*
*
*
*
*
*
*
Language
ISSN
0971-4065
Abstract
Antineutrophil cytoplasmic antibody (ANCA)--associated vasculitis (AAV) patients particularly presenting as rapidly progressive glomerulonephritis (RPGN) are at extremely high risk of progressing to end-stage kidney disease (ESKD); therefore, timely intervention is important. We describe our experience of managing six AAV patients who were on treatment (induction phase) and developed COVID-19. Cyclophosphamide was stopped till RT-PCR for SARS-CoV-2 was reported negative and patient had improved symptomatically. Out of our six patients, one died. Subsequently, cyclophosphamide was successfully resumed in all the surviving patients. In patients of AAV with COVID-19, close monitoring and withholding of cytotoxic medication and continuing steroids till active infection subsides is an effective treatment strategy until more and more data from well-conducted largescale studies become available for guidance. [ABSTRACT FROM AUTHOR]